IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Bank of Montreal Can

Bank of Montreal Can trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 243,191 shares of the medical research company's stock after selling 2,520 shares during the period. Bank of Montreal Can owned approximately 0.13% of IQVIA worth $57,099,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of IQV. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the 2nd quarter worth $27,000. Capital Performance Advisors LLP acquired a new stake in IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA in the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA in the 2nd quarter valued at about $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.1 %

Shares of IQV stock traded up $0.20 on Thursday, hitting $201.43. The stock had a trading volume of 822,837 shares, compared to its average volume of 1,177,509. The firm has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. The stock's 50 day moving average is $220.36 and its 200-day moving average is $226.57. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IQV. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a report on Tuesday, November 5th. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Argus upgraded shares of IQVIA to a "strong-buy" rating in a report on Wednesday, July 31st. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, Leerink Partners reissued an "outperform" rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.